title: Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
authors.affiliation: Department of Hematology and Oncology, University of Bochum, Marienhospital Herne, Herne, Germany. dirk.strumberg@marienhospital-herne.de
authors.forename: D
authors.initials: D
authors.lastname: Strumberg
authors.forename: B
authors.initials: B
authors.lastname: Schultheis
authors.forename: M E
authors.initials: ME
authors.lastname: Scheulen
authors.forename: R A
authors.initials: RA
authors.lastname: Hilger
authors.forename: J
authors.initials: J
authors.lastname: Krauss
authors.forename: N
authors.initials: N
authors.lastname: Marschner
authors.forename: F
authors.initials: F
authors.lastname: Lordick
authors.forename: F
authors.initials: F
authors.lastname: Bach
authors.forename: D
authors.initials: D
authors.lastname: Reuter
authors.forename: L
authors.initials: L
authors.lastname: Edler
authors.forename: K
authors.initials: K
authors.lastname: Mross
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C501466:nimotuzumab; D066246:ErbB Receptors